摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(4-propylphenyl)propanoic acid | 162752-13-8

中文名称
——
中文别名
——
英文名称
3-(4-propylphenyl)propanoic acid
英文别名
3-(4-n-propylphenyl)propanoic acid;4-Propylbenzenepropanoic acid
3-(4-propylphenyl)propanoic acid化学式
CAS
162752-13-8
化学式
C12H16O2
mdl
——
分子量
192.258
InChiKey
WRBXYOSHIVEUNT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    318.9±11.0 °C(Predicted)
  • 密度:
    1.052±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    14
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    37.3
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-(4-propylphenyl)propanoic acid三氯化铝草酰氯 作用下, 以 二氯甲烷 为溶剂, 生成 6-Propyl-2,3-dihydroinden-1-one
    参考文献:
    名称:
    The discovery and synthesis of novel adenosine receptor (A2A) antagonists
    摘要:
    In high throughput screening of our file compounds, a novel structure 1 was identified as a potent A(2A) receptor antagonist with no selectivity over the A(1) adenosine receptor. The structure-activity relationship investigation using 1 as a template lead to identification of a novel class of compounds as potent and selective antagonists of A(2A) adenosine receptor. Compound 26 was identified to be the most potent A(2A) receptor antagonist (K-i = 0.8 nM) with 100-fold selectivity over the A(1) adenosine receptor. (c) 2005 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2005.01.019
  • 作为产物:
    描述:
    4-丙基苯甲醛 在 palladium 10% on activated carbon 氢气 作用下, 以 吡啶乙醇乙酸乙酯 为溶剂, 80.0 ℃ 、549.5 kPa 条件下, 反应 18.0h, 生成 3-(4-propylphenyl)propanoic acid
    参考文献:
    名称:
    WO2008/112368
    摘要:
    公开号:
  • 作为试剂:
    参考文献:
    名称:
    PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS
    摘要:
    本发明提供苯基烷基羧酸化合物及含有此类化合物的组合物,有助于传递生物活性物质。
    公开号:
    US20110046050A1
点击查看最新优质反应信息

文献信息

  • Tyrosine phosphatase inhibitors
    申请人:——
    公开号:US20030144338A1
    公开(公告)日:2003-07-31
    A compound of the formula (I): 1 wherein X 1 and X 2 are the same or different and each is a bond or a spacer having 1 to 20 atom(s) in the main chain; one of R 1 and R 2 is a cycle group having substituent(s) selected from 1) an optionally substituted carboxy-C 1-6 alkoxy group and 2) an optionally substituted carboxy-C 1-6 aliphatic hydrocarbon group, wherein the cycle group optionally has additional substituent(s), and the other is an optionally substituted cycle group or a hydrogen atom; and R 3 , R 4 and R 5 are the same or different and each is a hydrogen atom or a substituent, or R 4 may link together with R 3 or R 5 to form an optionally substituted ring; provided that when R 3 is a hydrogen atom, R 4 is a hydrogen atom and R 5 is methyl, X 2 —R 2 is not 4-cyclohexylphenyl; when R 3 is 4-methoxyphenyl, R 4 is a hydrogen atom and R 5 is methyl, X 2 —R 2 is not 4-methoxyphenyl; and when R 1 or R 2 is a hydrogen atom, the adjacent X 1 or X 2 is not a C 1-7 alkylene; or a salt thereof exhibits a protein tyrosine phosphatase inhibitory action and is useful as a prophylactic or therapeutic agent for diabetes or the like.
    式(I)的化合物: 其中X1和X2相同或不同,每个都是主链中具有1至20个原子的键或间隔物; R1和R2中的一个是具有取代基的环基,所述取代基选自1)可选择地取代的羧基-C1-6烷氧基和2)可选择地取代的羧基-C1-6脂肪烃基,其中所述环基可选择地具有额外的取代基,另一个是可选择地取代的环基或氢原子;以及 R3、R4和R5相同或不同,每个是氢原子或取代基,或R4可以与R3或R5结合形成可选择地取代的环; 但是当R3是氢原子时,R4是氢原子且R5是甲基时,X2—R2不是4-环己基苯基;当R3是4-甲氧基苯基,R4是氢原子且R5是甲基时,X2—R2不是4-甲氧基苯基;当R1或R2是氢原子时,相邻的X1或X2不是C1-7烷基; 或其盐具有蛋白酪氨酸磷酸酶抑制作用,并且可用作糖尿病等疾病的预防或治疗剂。
  • PROGRAMMED DEGRADATION OF POLYMERS DERIVED FROM BIOMASS
    申请人:Sivaguru Jayaraman
    公开号:US20160108172A1
    公开(公告)日:2016-04-21
    Novel photodegradable polymers derived from biomass are provided, together with methods of making and methods of using said polymers.
    提供了从生物质中衍生的新型光降解聚合物,以及制备和使用该聚合物的方法。
  • Bisphosphonate squalene synthetase inhibitors
    申请人:E.R. SQUIBB & SONS, INC.
    公开号:EP0513761A2
    公开(公告)日:1992-11-19
    Compounds which are inhibitors of cholesterol biosynthesis (by inhibiting de novo squalene biosynthesis), and thus are useful as hypocholesterolemic agents and antiatherosclerotic agents are provided which have the structure and analogs thereof, wherein R¹, R², R³ and R⁴ are the same or different and are H, lower alkyl, a metal ion or a prodrug ester;    R⁵ is H, halogen or lower alkyl;    Zq is substituted alkenyl, substituted alkynyl, mixed alkenyl-alkynyl or substituted phenylalkyl, or substituted biphenylalkyl, alkylphenylalkyl or alkyl, including all stereoisomers thereof. New methods for using such compounds to inhibit cholesterol biosynthesis are also provided.
    所提供的化合物是胆固醇生物合成的抑制剂(通过抑制角鲨烯的新生物合成),因此可用作降胆固醇药和抗动脉粥样硬化药,其结构为 及其类似物,其中 R¹、R²、R³ 和 R⁴ 相同或不同,并且是 H、低级烷基、金属离子或原药酯; R⁵ 是 H、卤素或低级烷基; Zq 是取代的烯基、取代的炔基、混合烯基-炔基或取代的苯基烷基,或取代的联苯烷基、 烷基苯烷基或烷基,包括其所有立体异构体。 还提供了使用此类化合物抑制胆固醇生物合成的新方法。
  • TYROSINE PHOSPHATASE INHIBITORS
    申请人:Takeda Chemical Industries, Ltd.
    公开号:EP1284260A1
    公开(公告)日:2003-02-19
    A compound of the formula (I):    wherein X1 and X2 are the same or different and each is a bond or a spacer having 1 to 20 atom(s) in the main chain;    one of R1 and R2 is a cycle group having substituent(s) selected from 1) an optionally substituted carboxy-C1-6 alkoxy group and 2) an optionally substituted carboxy-C1-6 aliphatic hydrocarbon group, wherein the cycle group optionally has additional substituent(s), and the other is an optionally substituted cycle group or a hydrogen atom; and    R3, R4 and R5 are the same or different and each is a hydrogen atom or a substituent, or R4 may link together with R3 or R5 to form an optionally substituted ring;    provided that when R3 is a hydrogen atom, R4 is a hydrogen atom and R5 is methyl, X2-R2 is not 4-cyclohexylphenyl; when R3 is 4-methoxyphenyl, R4 is a hydrogen atom and R5 is methyl, X2-R2 is not 4-methoxyphenyl; and when R1 or R2 is a hydrogen atom, the adjacent X1 or X2 is not a C1-7 alkylene; or a salt thereof exhibits a protein tyrosine phosphatase inhibitory action and is useful as a prophylactic or therapeutic agent for diabetes or the like.
    式(I)化合物: 其中 X1 和 X2 相同或不同,且各自为键或在主链中具有 1 至 20 个原子的间隔物; R1 和 R2 中的一个是具有选自 1)任选取代的羧基-C1-6 烷氧基和 2)任选取代的羧基-C1-6 脂肪族烃基的取代基的循环基团,其中循环基团任选具有附加取代基,另一个是任选取代的循环基团或氢原子;以及 R3、R4 和 R5 相同或不同,且各自为氢原子或取代基,或 R4 可与 R3 或 R5 连接形成任选取代的环; 条件是当 R3 是氢原子、R4 是氢原子且 R5 是甲基时,X2-R2 不是 4-环己基苯基;当 R3 是 4-甲氧基苯基、R4 是氢原子且 R5 是甲基时,X2-R2 不是 4-甲氧基苯基;以及当 R1 或 R2 是氢原子时,相邻的 X1 或 X2 不是 C1-7 亚烷基; 或其盐具有蛋白酪氨酸磷酸酶抑制作用,可用作糖尿病或类似疾病的预防或治疗剂。
  • Phenylalkylcarboxylic acid delivery agents
    申请人:Emisphere Technologies, Inc.
    公开号:US10456472B2
    公开(公告)日:2019-10-29
    The present invention provides phenylalkylcarboxylic acid compounds and compositions containing such compounds which facilitate the delivery of biologically active agents.
    本发明提供了苯基烷基羧酸化合物和含有此类化合物的组合物,它们有助于生物活性剂的递送。
查看更多